KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $316.9 million.

  • Ionis Pharmaceuticals' Operating Expenses rose 1218.93% to $316.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 609.79%. This contributed to the annual value of $1.2 billion for FY2024, which is 340.31% up from last year.
  • Ionis Pharmaceuticals' Operating Expenses amounted to $316.9 million in Q3 2025, which was up 1218.93% from $312.2 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Operating Expenses' 5-year high stood at $359.9 million during Q4 2022, with a 5-year trough of $198.7 million in Q2 2021.
  • Its 5-year average for Operating Expenses is $266.7 million, with a median of $278.5 million in 2025.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Operating Expenses tumbled by 2989.09% in 2021, and later skyrocketed by 6404.01% in 2022.
  • Ionis Pharmaceuticals' Operating Expenses (Quarter) stood at $219.4 million in 2021, then skyrocketed by 64.04% to $359.9 million in 2022, then decreased by 8.14% to $330.6 million in 2023, then grew by 2.05% to $337.4 million in 2024, then fell by 6.08% to $316.9 million in 2025.
  • Its Operating Expenses stands at $316.9 million for Q3 2025, versus $312.2 million for Q2 2025 and $278.5 million for Q1 2025.